AAM to Congress: Pass key bills considered by the Senate HELP Committee AAM commended the slated mark up by the Senate Health, Education, Labor and Pensions Committee of two pieces of legislation. Hikma launches foscarnet sodium injectionThe product is indicated for the treatment of CMV retinitis in patients with AIDS. AAM: Generic medicines increase patient access more than government negotiated price controls AAM is urging Congress and regulators to stop patent abuses and streamline approvals. FDA gives Lupin approval for bumetanide injection Bumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic disease and renal disease. Biosimilars Council urges House to pass patent thicket legislation S. 150 passed the Senate and was placed on the House of Representatives' suspension calendar. Alembic intros acitretin capsules Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Alembic intros fluphenazine hydrochloride tablets Fluphenazine hydrochloride tablets are are indicated in the management of manifestations of psychotic disorders. AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERA The Association for Accessible Medicines and its Biosimilars Council oppose passage of the PREVAIL Act and the PERA Act. Former FDA commissioner Scott Gottlieb will keynote AAM's annual meeting Scott Gottlieb also will moderate the CEOs Unplugged session, where healthcare executives will share their candid insights and industry perspectives. AAM, Biosimilar Council host patent abuse Congressional briefing AAM, The ERISA Industry Committee and Transparency-Rx sent a letter to Congressional leaders urging prompt legislative action. First Previous 22 23 24 25 26 Next Last
